Ascendis Pharma

Ascendis Pharma is a global biopharmaceutical company focused on developing innovative therapies using its proprietary TransCon technology platform. The company addresses unmet medical needs in endocrinology, rare diseases, and oncology, guided by its core values of Patients, Science, and Passion. Founded as a developmental-stage company, Ascendis Pharma has evolved into a fully integrated biopharma leader with a strong portfolio that includes two U.S. FDA-approved therapies and several late-stage assets. Headquartered in Denmark, Ascendis Pharma has research facilities in Germany and offices across Europe and the United States, including locations in Palo Alto, CA, and Princeton, NJ. The TransCon platform enables the creation of prodrug therapies that activate at target sites, supporting programs across multiple therapeutic categories. The company actively collaborates with global partners to enhance treatment safety, efficacy, tolerability, and convenience, while also engaging with medical communities through patient-centric initiatives.